Simplify's take
What believers are saying
- Biocodex launched a €15 million live biotherapeutics platform on November 5, 2026.
- The MRM Health partnership and 2025 Series B position Biocodex inside CORAL commercialization.
- Biocodex funded September 2026 Phase 3 filings for Batten-1 across FDA, MHRA, CTIS.
What critics are saying
- Biocodex filed October 15, 2026 litigation at the U.S. Court of International Trade.
- The €15 million Beauvais platform produces no commercial microbiome revenue before 2030.
- If MH002 and Batten-1 fail Phase 3, Biocodex’s microbiome strategy loses credibility.
What makes Biocodex unique
- Biocodex combines 70 years of microbiome expertise with manufacturing scale.
- It sells in 100 countries through affiliates and partners, not one-market dependence.
- Its Beauvais site already ships 95 million packs annually, enabling rapid industrialization.
Help us improve and share your feedback! Did you find this helpful?